AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03499665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Releasing Maneuvers and Home Exercises Group
Description: In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
Study NCT03499665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
Study NCT02559843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Study NCT02559843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Study NCT00305682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
Study NCT02749695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melsmon
Description: Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
Study NCT02749695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
Study NCT03694197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praluent
Description: Subcutaneous (SC) administration
Study NCT00996697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/formoterol and tiotropium
Description: Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
Study NCT02555358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel,0xaliplatin,capecitabine
Description: docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
Study NCT02555358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin,capecitabine
Description: oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
Study NCT01215162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative radiation to tumor bed
Description: IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
Study NCT03167424 — intervention group
Intervention type: DEVICE
Intervention: Treatment of restenosis
Description: Treatment of in-stent restenosis
Study NCT01718106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantation of a bioabsorbable polymer DES
Description: implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
Study NCT03173508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study NCT03173508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study NCT03615430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus plane block with local anesthetic
Description: The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
Study NCT03285113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GiMer Medical MN 1000 External Stimulator
Description: Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
Study NCT00508339 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Toronto Extremity Salvage Score (TESS) questionnaire.
Study NCT03615430 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: serratus plane block with saline
Description: The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
Study NCT00996697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide/formoterol and placebo
Description: Symbicort 200/6 2puff bid and placebo
Study NCT02438735 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic endometrioma excision
Study NCT02438735 — intervention group
Intervention type: OTHER
Intervention: Conservative follow up
Study NCT03198663 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: POSSE
Description: Popular-opinion leader
Study NCT03198663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POSSE
Description: Popular-opinion leader
Study NCT01140438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin+ NPH insulin
Description: Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
Study NCT01140438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin + sitagliptin +/- repaglinide
Description: Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
Study NCT04580784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weekly hypofractionation for early breast cancer
Description: Testing the feasibility of a hypofractionated adjuvant radiotherapy regimen after breast surgery on a-once-weekly basis for a total dose of 28.5Gy in 5 fractions over 5 weeks
Study NCT03097445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: mailed 5-week course of Habitrol® transdermal nicotine patches
Study NCT02871076 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
Study NCT02871076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
Study NCT03724890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
Study NCT03724890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3814
Description: Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
Study NCT03724890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
Study NCT03724890 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
Study NCT01751087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: oral mifepristone 200 mg on Day 1.
Study NCT01751087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: buccal misoprostol 400 mcg on Day 2
Study NCT01751087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic dilators
Description: osmotic dilators on Day 1
Study NCT01751087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Osmotic dilators
Description: osmotic dilators on Day 1
Study NCT01751087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo for mifepristone, on day 1
Study NCT01751087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: placebo for mifepristone, on day 1
Study NCT01751087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo for misoprostol, on day 2
Study NCT01751087 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: placebo for misoprostol, on day 2
Study NCT03648580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Complete powder
Description: Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
Study NCT03648580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: verbal nutrition education
Description: give the verbal nutrition education
Study NCT03648580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal nutrition education
Description: give the verbal nutrition education
Study NCT02484807 — intervention group
Intervention type: OTHER
Intervention: no intervention, only observation of different groups
Study NCT03895879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab sc (162 mg) once every 2 weeks
Study NCT03895879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab sc (162 mg) once every week
Study NCT04334863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1066
Description: WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Study NCT01277835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: Infusion of lidocaine 3mg/min or 2mg/min during surgery
Study NCT01277835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Infusion at same rate as experimental arm
Study NCT02349763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone
Description: Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
Study NCT02349763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Dexamethasone
Description: Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
Study NCT02643407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 60mg/m2
Study NCT02643407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60mg/m2
Study NCT02643407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: 80mg/m2
Study NCT02643407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2
Study NCT02469363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
Study NCT02469363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mc-Coy laryngoscope
Description: Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
Study NCT02469363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac videolaryngoscope
Description: Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
Study NCT02469363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope
Description: Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
Study NCT02220049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT03993535 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: selective serotonin reuptake inhibitor
Description: open treatment based on patient preference and treatment availability
Study NCT02943538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
Study NCT02943538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telephone
Description: A telephone control of their state and evolution will be made through the nursing staff of the unit.
Study NCT02943538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Conventional care provided in the unit to patients with IBD -high moderate complexity.
Study NCT00922896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
Description: * Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks
Study NCT02266407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aquamantys System
Description: The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
Study NCT04454307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: tramadol 100 mg twice daily for 10 days
Study NCT04454307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care delivered in the isolation hospitals.
Description: Oxygen ventilation.
Study NCT01296607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 2
Description: Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Study NCT01296607 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 3
Description: Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Study NCT04738669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The mHealth intervention includes telephonic call and SMS.
Study NCT04738669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teach-back
Description: While the teach-back includes counselling session related to discharge instruction including medication adherence.
Study NCT00559117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111
Description: A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
Study NCT03862053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Manuka honey
Description: manuka eyedrops applied to the ocular surface
Study NCT03862053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Manuka honey
Description: manuka eyedrops applied to the ocular surface
Study NCT00382928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation of pulseless VT/VF by AECD
Description: In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
Study NCT01052428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate (Toprol XL)
Description: Toprol XL 100 mg once a day for 2 years
Study NCT01052428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100 mg once a day for 2 years
Study NCT03283995 — intervention group
Intervention type: OTHER
Intervention: Cardiac Volume Monitoring VolumeView
Description: hemodynamic measure
Study NCT03283995 — intervention group
Intervention type: DEVICE
Intervention: echocardiography
Description: hemodynamic measure
Study NCT02635789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12G gel
Description: NPC-12G gel is administered topically twice a day for 12 weeks
Study NCT02635789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: NPC-12G gel placebo is administered topically twice a day for 12 weeks
Study NCT03043820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Oral selective estrogen receptor modulator (SERM).
Study NCT03043820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in form and color to intervention.
Study NCT03012152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative breast surgery
Study NCT03012152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oncoplastic breast surgery
Study NCT00597792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NDO Full-thickness Plicator
Description: A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
Study NCT03090035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α2
Description: Peg-INF was given in a dose of 180 μg/week
Study NCT03090035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3
Study NCT02376439 — intervention group
Intervention type: OTHER
Intervention: Kool-aid
Description: Participant drank two different types of kool-aid (sugar free and regular)